Recursion (RXRX) news
Recent news
Recursion Pharmaceuticals shares fall 6.8% after Q2 revenue miss
Recursion Pharmaceuticals (NASDAQ: RCRN) experienced a 6.8% decline in its stock price following the release of its second-quarter financial results, which showed a revenue shortfall compared to expectations. The company reported Q2 revenue of $38.5 million , below the projected $42.1 million. This…
AInvest Wire · Aug 5, 2026Recursion Pharmaceuticals shares fall 9% premarket after Q2 revenue miss
Recursion Pharmaceuticals (NASDAQ: RXRX) shares fell 9% in pre-market trading on July 31, 2026, following the company’s second-quarter 2026 financial results, which showed revenue below expectations . The stock opened at $3.09, down from the previous close of $3.04, with trading ranging between…
AInvest Wire · Aug 5, 2026Recursion Pharma 2Q loss/share 25c, est. loss/share 23c
AInvest Wire · Aug 5, 2026Recursion Pharmaceuticals Inc: reduced 2026 cash operating expense guidance to <$375 mln
AInvest Wire · Aug 5, 2026Heavy Rare Earths - appoints Jason Barnett as managing director and CEO effective immediately
Heavy Rare Earths has announced the appointment of Jason Barnett as managing director and CEO, effective immediately. Barnett, a seasoned executive with extensive experience in real estate and corporate leadership, brings a strong background in strategic transactions and capital markets to the…
AInvest Wire · Jun 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.